Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA) Results highlight the potential of MAVENCLAD to reduce neurodegeneration and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results